Natural killer cell therapy(NCI)(Natural killer cell therapy(NCI)) - 在研适应症：浆细胞白血病_专利_临床

概要

基本信息

药物类型

免疫细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

癌症免疫系统疾病心血管疾病+ [2]

在研适应症

浆细胞白血病

非在研适应症

急性双表型白血病复发性急性淋巴细胞白血病加速期慢性骨髄性白血病+ [24]

原研机构

National Cancer Institute

在研机构

National Cancer Institute

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

9

项与 Natural killer cell therapy(NCI) 相关的临床试验

NCT04991870 / Recruiting临床1期IIT

A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Glioblastoma

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.

开始日期2023-04-28

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT05143125 / Unknown status临床1/2期IIT

Clinical Study of Decitabine Combined With NK Cell Infusion in the Treatment of Malignant Tumors

Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%.

开始日期2021-02-05

申办/合作机构

Shenzhen University General Hospital

NCT03420963 / Recruiting临床1期IIT

Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults

This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer [NK] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Drugs used in chemotherapy, such as cyclophosphamide and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NK cells together with cyclophosphamide and etoposide may work better in treating children and young adults with solid tumors.

开始日期2018-08-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与 Natural killer cell therapy(NCI) 相关的临床结果

登录后查看更多信息

100 项与 Natural killer cell therapy(NCI) 相关的转化医学

登录后查看更多信息

100 项与 Natural killer cell therapy(NCI) 相关的专利（医药）

登录后查看更多信息

1

项与 Natural killer cell therapy(NCI) 相关的文献（医药）

2017-11-01·Bioresource technology1区 · 工程技术

Development of natural cellulase inhibitor mediated intensified biological pretreatment technology using Pleurotus florida for maximum recovery of cellulose from paddy straw under solid state condition

1区 · 工程技术

Article

作者: Kirupa Sankar, Muthuvelu ; Naresh Kumar, Manickam ; Ravikumar, Rajarathinam ; Thenmozhi, Senniyappan

Inhibitor mediated intensified bio-pretreatment (IMBP) technology using natural cellulase inhibitor (NCI) for maximum cellulose recovery from paddy straw was studied. Pretreatment was carried out under solid state condition. Supplementation of 8% NCI in pretreatment medium improves cellulose recovery and delignification by 1.2 and 1.5-fold respectively, compared to conventional bio-pretreatment due to inhibition of 61% of cellulase activity in IMBP. Further increase in NCI concentration showed negative effect on Pleurotus florida growth and suppress the laccase productivity by 1.1-fold. Laccase activity in IMBP was found to be 2.0U/mL on 19^thday, which is higher than (1.5U/mL) conventional bio-pretreatment. Physico-chemical modifications in paddy straw before and after pretreatment were analysed by SEM, ATR-FTIR, XRD and TGA. According to these findings, the IMBP technology can be a viable eco-friendly technology for sustainable production of bioethanol with maximum cellulose recovery.

100 项与 Natural killer cell therapy(NCI) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性B细胞淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
复发性弥漫性大B细胞淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
难治性弥漫性大 B 细胞淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
套细胞淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
复发性滤泡性淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
复发性惰性非霍奇金淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
难治性滤泡性淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
难治性惰性成人非霍奇金淋巴瘤	临床2期	美国	National Cancer Institute	2017-10-10
浆细胞白血病	临床2期	美国	National Cancer Institute	2013-06-10
室管膜瘤	临床1期	美国	National Cancer Institute	2015-03-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03019640 (CTgov)	临床2期	复发性滤泡性淋巴瘤 \| 套细胞淋巴瘤 \| 难治性滤泡性淋巴瘤 ... 更多	22	Lenalidomide+Autologous Hematopoietic Stem Cell Transplantation+Etoposide+Cord Blood-derived Expanded Allogeneic Natural Killer Cells+Carmustine+Melphalan+Filgrastim+Rituximab+Cytarabine	鏇遞窪夢構鏇艱觸襯廠(餘醖遞鹹窪獵衊膚夢壓) = 鑰願齋膚獵顧廠衊獵夢餘餘鹹繭壓範醖遞構鹽 (艱夢憲鏇壓鑰醖窪製鏇, 糧廠鏇餘遞願選窪願網 ~ 簾觸醖範繭齋襯壓鏇衊) 更多	-	2023-02-16